[ Price : $8.95]
FDA says an Acorda Therapeutics NDA for Inbrija is not sufficiently complete to permit a substantive review.[ Price : $8.95]
FDA approves a firmware update to Abbott (St. Jude) implantable pacemakers to correct a cybersecurity vulnerability that could lea...[ Price : $8.95]
Federal Register notice: FDA announces medical device user fee rates and payment procedures for fiscal year 2018.[ Price : $8.95]
FDA approves a Boehringer Ingelheim Pharmaceuticals BLA for Cyltezo, a biosimilar version of Abbotts Humira (adalimumab) for multi...[ Price : $8.95]
Merck says its investigational drug anacetrapib reduced risk of major coronary events in patients with atherosclerotic vascular di...[ Price : $8.95]
Bristol-Myers Squibb and Daiichi Sankyo say they are collaborating on a Phase 1b clinical trial of Opdivo and an investigational D...[ Price : $8.95]
FDA explains its biomarker qualification context of use statement.[ Price : $8.95]
Federal Register notice: FDA announces fiscal year 2018 rates for generic drug user fees.